A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

@article{Mackenzie2005API,
  title={A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer},
  author={Mary J. Mackenzie and Holger W. Hirte and Goss Glenwood and Maroun Jean and Rakesh Goel and Pierre P. Major and Wilson H. Miller and Lawrence Panasci and Ian A.J . Lorimer and Gerald Batist and Sarah Matthews and Lynn Douglas and Lesley Seymour},
  journal={Investigational New Drugs},
  year={2005},
  volume={23},
  pages={165-170}
}
Purpose: The epidermal growth factor receptor (EGFR) appears relevant in the pathogenesis and progression of colorectal cancer. After completing a phase I pharmacodynamic trial of ZD1839, we undertook a dose expansion trial to examine the antitumour efficacy and adverse effect profile of this agent in a homogeneous group of patients with metastatic colorectal cancer (CRC). Experimental design: Eligible patients with metastatic or recurrent CRC received ZD1839 750 mg daily by mouth. This dose… CONTINUE READING
Highly Cited
This paper has 27 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2008
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 23 references

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 2 Excerpts

Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecanrefractory metastatic colorectal cancer

D Cunningham, Y Humblet, +7 authors E Van Cutsem
Proc Am Soc Clin Oncol abstract 1012, • 2003
View 2 Excerpts

Results of a phase I trial of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumours

M Tewes, N Schleucher, +7 authors U Vanhoefer
Proc Am Soc Clin Oncol abstract 378, • 2002
View 1 Excerpt

Single Agent IMC - C 225 ( Erbitux ) has activity in CPT - 11 - refractory colorectal cancer that expresses the epidermal growth factor recep

L Saltz, NJ Meropol, +3 authors RJ Mayer
Proc Am Soc Clin Oncol abstract 504 , • 2002